DrugBank ID: db01041
Synonymous :(+-)-n-(2,6-dioxo-3-piperidyl)phthalimide | (+-)-thalidomide | (±)-n-(2,6-dioxo-3-piperidyl)phthalimide | (±)-thalidomide | 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline | 2,6-dioxo-3-phthalimidopiperidine | 3-phthalimidoglutarimide | alpha-(n-phthalimido)glutarimide | alpha-n-phthalylglutaramide | n-(2,6-dioxo-3-piperidyl)phthalimide | n-phthaloylglutamimide | n-phthalyl-glutaminsaeure-imid | n-phthalylglutamic acid imide | talidomida | thalidomide | thalidomidum | α-(n-phthalimido)glutarimide | α-n-phthalylglutaramide | α-phthalimidoglutarimide
Drug Sentece Context
Table 1. Analysis of context sentence of thalidomide gene in 7 abstracts.
|32549297||This review also reports the rationale for a possible use of drugs commonly employed in neoplastic therapy, such as bevacizumab, ibrutinib, selinexor, thalidomide, carfilzomib, and PD-1 inhibitors, for the treatment of SARS-CoV-2 infection.|
|32568969||These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin α-1, IL-6, tocilizumab, cyclosporine, thalidomide, fingolimod), Chinese medicines (i.e. glycyrrhizin, baicalin, Xuebijing), anti-vascular endothelial growth factors (bevacizumab), estrogen modulating drugs, statins and nutritional supplements (i.e. vitamin A, B, C, D, E and zinc).|
|32574274||Among these drugs is Thalidomide; a historically emblematic controversial molecule that harbors an FDA approval for treating erythema nodosum leprosum (ENL) and multiple myeloma (MM). […] Based on just one-case report that presented positive outcomes in a patient treated amongst others with Thalidomide, two clinical trials on the efficacy and safety of Thalidomide in treating severe respiratory complications in COVID-19 patients were registered. […] Yet, the absence of substantial evidence on Thalidomide usage in that context along with the discontinued studies on the efficiency of this drug in similar pulmonary diseases, might cause a significant obstacle for carrying out further clinical evaluations. […] Herein, we will discuss the theoretical effectiveness of Thalidomide in attenuating inflammatory complications that are encountered in COVID-19 patients while pinpointing the lack of the needed evidences to move forward with this drug.|